Biose Industrie

Biose Industrie is a French company that specializes in bioproduction, focusing on microbiome therapeutics and Next Generation Probiotics, contributing significantly to the evolving pharmaceutical landscape. Founded in 1951, Biose Industrie operates in the bioproduction sector, developing microbiome-based therapeutics. The company has seen a recent investment shift, acquiring a majority stake through a BUYOUT valued at EUR 80 mn on February 17, 2023, led by Bpifrance Investissement and L-GAM Advisers. The CEO is Adrien Nivoliez, who has been instrumental in guiding the company's strategic direction.

The firm operates primarily out of France. Biose Industrie specializes in the bioproduction of microbiome therapeutics, primarily through Live Biotherapeutic Products (LBPs) that leverage particular strains of microorganisms to address various health conditions. With over 30 clinical lines and more than 300 strains in development, Biose caters to pharmaceutical companies and research organizations, facilitating the transition from project development to commercial launch across markets in Europe and North America. In 2023, Biose Industrie reported a revenue of EUR 41,967,446.

20 and an EBITDA of EUR 10,229,768. The company's revenue is generated through contract development and manufacturing partnerships with pharmaceutical clients, highlighting its established history since 1951 that aids in securing ongoing contracts. Following the recent acquisition in February 2023, Biose Industrie plans to scale its workforce to 500 employees and expand its applied R&D facility near Boston, USA. The company aims to launch new microbiome therapeutics in the coming years while targeting growth in North America and expanding its reach into emerging markets.

The EUR 80 mn funding will facilitate these initiatives, allowing Biose to enhance its research capabilities and operational capacity.